Madrigal Pharmaceuticals Balance Sheet
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals financial position
At the end of fiscal 2025, Madrigal Pharmaceuticals reported total assets of $1.26 billion, up 20.9% from a year earlier against total liabilities of $656.9 million. Shareholders' equity stood at $602.7 million, or 47.8% of assets. The company held $198.7 million in cash and equivalents against $339.9 million of debt, a net debt position of $141.2 million.
The current ratio (current assets divided by current liabilities) was 4.01, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.56.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 19.14M |
| Short-Term Investments | 784.87M | 826.23M | 534.22M | 27.23M | 234.08M | 230.15M | 392.35M | 426.34M | 42.90M | 21.36M |
| Receivables | 134.48M | 53.82M | 0 | — | — | — | — | — | — | — |
| Inventory | 74.84M | 34.07M | 0 | — | — | — | — | — | — | — |
| Total Current Assets | 1.25B | 1.03B | 637.28M | 361.37M | 271.68M | 285.16M | 440.20M | 485.20M | 192.01M | 41.21M |
| Property, Plant & Equipment | 1.50M | 2.19M | 1.55M | 601.00K | 851.00K | 1.05M | 1.18M | 227.00K | 301.00K | 3.00K |
| Intangible Assets | 7.38M | 4.73M | 0 | — | — | — | — | — | — | — |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M |
| Accounts Payable | 48.88M | 43.60M | 28.04M | 23.83M | 21.38M | 1.02M | 1.18M | 2.49M | 1.93M | 762.00K |
| Total Current Liabilities | 310.29M | 169.28M | 118.55M | 115.89M | 76.84M | 46.56M | 25.13M | 8.44M | 10.05M | 4.80M |
| Long-Term Debt | 339.88M | 117.57M | 115.48M | 49.29M | 0 | — | — | — | — | — |
| Total Liabilities | 656.90M | 287.86M | 235.21M | 165.18M | 77.22M | 47.02M | 25.49M | 8.44M | 10.05M | 4.80M |
| Shareholders' Equity | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M |
| Retained Earnings | -2.09B | -1.80B | -1.34B | -962.66M | -667.31M | -425.46M | -223.22M | -139.27M | -106.46M | -75.31M |
| Total Debt | 339.88M | 117.57M | 115.48M | 49.29M | 0 | — | — | — | — | — |
| Net Cash (Debt) | 643.68M | 808.68M | 518.65M | 309.49M | 270.35M | 284.15M | 439.05M | 483.72M | 191.53M | 40.50M |
| Shares Outstanding | 22.84M | 22.00M | 19.88M | 18.10M | 17.10M | 15.51M | 15.43M | 15.41M | 14.23M | 11.95M |
This table shows 10 annual periods of Madrigal Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a balance sheet?